GlobalResearch and clinical trials
Stem cell transplant in STAT3 hyper-IgE syndrome: five-year survival of 93% in 41 patients
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
Worldwide, 41 patients with hyper-IgE syndrome who had a stem cell transplant were studied. The median age at transplant was 14. The five-year survival rate was 93%. Lung and skin infections decreased in most patients. However, one in five had a new bone fracture after the transplant.
What does it mean for patients and families?
Transplantation may be an option for selected patients with severe infections. However, problems outside the immune system, such as bone problems, may continue. The transplant decision is made at a specialist center.
Source
Scientific paper: Allogeneic hematopoietic stem cell transplantation for STAT3 hyper-IgE syndrome: a worldwide study. Blood Advances, 2025. DOI: 10.1182/bloodadvances.2025016158 · PubMed 40540800
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Autosomal dominant hyper-IgE syndrome (Job syndrome)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.